Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 4/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | APEX1 | P27695 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL28086495 | 0.87 | NR1I2 (0.69) | NR1I2PGRPTGS1TDP1HSD17B10 | |
| Moxalactam SCHEMBL6521966 | 0.85 | NR1I2 (0.64) | NR1I2PGRPTGS1TDP1HSD17B10 | |
| Flomoxef SCHEMBL18065040 | 0.85 | NR1I2 (0.58) | NR1I2PGRPTGS1TDP1HSD17B10 | |
| Ceftriaxone SCHEMBL3389557 | 0.84 | NR1I2 (0.64) | NR1I2PGRPTGS1TDP1HSD17B10 | |
| Moxalactam SCHEMBL13723425 | 0.82 | PTGS1 (0.64) | NR1I2PGRPTGS1TDP1HSD17B10 | |
| Ceftazidime SCHEMBL715368 | 0.82 | NR1I2 (0.58) | NR1I2PGRPTGS1ESR1TDP1 | |
| SCHEMBL11463469 | 0.73 | NR1I2 (0.86) | NR1I2PGRTDP1HSD17B10MAPT | |
| SCHEMBL11463468 | 0.73 | NR1I2 (0.86) | NR1I2PGRTDP1HSD17B10MAPT | |
| Hydrochloric Acid SCHEMBL11481373 | 0.73 | NR1I2 (0.85) | NR1I2PGRTDP1HSD17B10MAPT | |
| Hydrochloric Acid SCHEMBL11481370 | 0.73 | NR1I2 (0.85) | NR1I2PGRTDP1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2020-07-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | NR1I2 3513/4885PGR 199/4885PTGS1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.